Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:53:26.301Z.
Calculation as of: 2026-10-06T19:53:26.301Z.
Quote observation: 2026-10-06T19:50:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6b8b16bed2a6fff21aaa666e30465ae2bcbbc8377d0ad77d6381797994f17b37
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$106.98M
EBITDA Yield
N/A
TTM Avg
5.35%
3Y Avg
4.92%
5Y Avg
4.17%
Market Cap
$106.44M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.20M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.37M
EBITDA Yield
205.93%
TTM Avg
162.58%
3Y Avg
142.94%
5Y Avg
38.81%
Market Cap
$109.12M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | $107.00M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A | 5.35% | 4.92% | 4.17% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $106.44M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.59M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $108.43M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.37M | 205.93% | 162.58% | 142.94% | 38.81% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.12M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
